{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:16:04Z","timestamp":1788196564555,"version":"build-2803163510"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Major Project during the 13th Five-Year Plan Period","award":["Grant No. 2017ZX10201201-002-001"],"award-info":[{"award-number":["Grant No. 2017ZX10201201-002-001"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite the clinical significance, data are limited on pregnancy outcomes and infant growth among women with chronic hepatitis B virus (HBV) infection treated with antiviral treatment before pregnancy (ATBP). This study aimed to evaluate the effects of ATBP on maternal pregnancy outcomes and infant growth parameters. A retrospective cohort study was conducted among 1031 women aged \u226520 years with singleton pregnancies and chronic HBV infection, recruited from January 2021 to January 2023. Propensity score matching was applied to balance baseline characteristics across 3 groups: 99 women receiving ATBP, 99 receiving antiviral treatment during pregnancy (ATDP), and 99 receiving no antiviral treatment. Pregnancy outcomes were analyzed using modified Poisson regression, while infant growth parameters were assessed by generalized linear regression, stratified by sex. After matching, mothers in the ATBP group exhibited a significantly lower risk of gestational abnormal alanine aminotransferase compared to those in the ATDP group. No significant differences were observed in maternal pregnancy outcomes (such as hypertensive disorders of pregnancy, gestational diabetes mellitus, and preterm birth) and in the growth parameters of their infants in the ATBP group versus the other 2 groups. Only 1 infant in this study, who was in the ATDP group and received antiviral treatment starting at 24 weeks of gestation, was diagnosed with chronic HBV infection. Our findings indicated that ATBP was associated with a lower risk of gestational alanine aminotransferase abnormalities in women with chronic HBV infection. However, we did not find a difference in maternal pregnancy outcomes or infant growth in the first year of life. These results provide insights for clinicians managing pregnancy in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049131","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:00:14Z","timestamp":1781600414000},"page":"e49131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Maternal and infant growth outcomes following preconception antiviral therapy in chronic hepatitis B virus infection: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Xing-Ran","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, and Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, and Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, and Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-8185","authenticated-orcid":false,"given":"Guorong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, and Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3350\/cmh.2023.0412","article-title":"Comprehensive approach to controlling chronic hepatitis B in China.","volume":"30","author":"Shan","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14309\/ajg.0000000000001575","article-title":"Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease.","volume":"117","author":"Cacoub","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.14218\/JCTH.2022.00047","article-title":"Management algorithm for prevention of mother-to-child transmission of hepatitis B virus (2022).","volume":"10","author":"Liu","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/jvh.13244","article-title":"Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings.","volume":"27","author":"Gane","year":"2020","journal-title":"J Viral Hepat"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.3390\/jcm10132926","article-title":"Hepatitis B virus infection in pregnancy: immunological response, natural course and pregnancy outcomes.","volume":"10","author":"Sirilert","year":"2021","journal-title":"J Clin Med"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"1122048","DOI":"10.3389\/fimmu.2023.1122048","article-title":"Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity.","volume":"14","author":"Lu","year":"2023","journal-title":"Front Immunol"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12072-021-10285-5","article-title":"Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy.","volume":"16","author":"Kumar","year":"2022","journal-title":"Hepatol Int"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/oby.20995","article-title":"Lower BMI cutoffs to define overweight and obesity in China.","volume":"23","author":"He","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update.","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"13631","DOI":"10.1038\/s41598-020-70644-4","article-title":"Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus.","volume":"10","author":"Pan","year":"2020","journal-title":"Sci Rep"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejogrb.2022.07.009","article-title":"Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: a cohort study.","volume":"276","author":"Li","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/liv.15873","article-title":"Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: maternal ALT trajectory and infant outcomes.","volume":"44","author":"Chen","year":"2024","journal-title":"Liver Int"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load.","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B.","volume":"378","author":"Jourdain","year":"2018","journal-title":"N Engl J Med"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jhep.2020.01.021","article-title":"Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate.","volume":"72","author":"Wen","year":"2020","journal-title":"J Hepatol"},{"key":"R24-20260831","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B.","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20260831","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.cgh.2021.12.012","article-title":"Tenofovir alafenamide for pregnant Chinese women with active chronic hepatitis B: a multicenter prospective study.","volume":"20","author":"Zeng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ijid.2021.03.023","article-title":"Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy.","volume":"105","author":"Shang","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"1031291","DOI":"10.3389\/fimmu.2022.1031291","article-title":"Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers-a prospective cohort study of 417 cases.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/ajg.2016.296","article-title":"Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B.","volume":"111","author":"Chang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/MCG.0000000000000877","article-title":"Baseline hepatitis B virus titer predicts initial postpartum hepatic flare: a multicenter prospective study.","volume":"52","author":"Liu","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"R31-20260831","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7150\/ijms.38410","article-title":"Pregnancy outcome of women with chronic hepatitis B who discontinued antiviral treatment before or in the early pregnancy.","volume":"17","author":"Gao","year":"2020","journal-title":"Int J Med Sci"},{"key":"R32-20260831","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13293-019-0261-7","article-title":"Sex differences in fetal growth and immediate birth outcomes in a low-risk Caucasian population.","volume":"10","author":"Galjaard","year":"2019","journal-title":"Biol Sex Differ"},{"key":"R33-20260831","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/gutjnl-2020-322719","article-title":"Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.","volume":"71","author":"Pan","year":"2022","journal-title":"Gut"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MCG.0000000000001779","article-title":"Efficacy and long-term safety of telbivudine usage during second or third trimester in hepatitis B surface antigen positive mothers with high viral load: a 10-year prospective study.","volume":"57","author":"Jiang","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/jbmr.4866","article-title":"Biochemical markers of calcium and bone metabolism during and after lactation in Ugandan women with HIV on universal maternal antiretroviral therapy.","volume":"38","author":"Nabwire","year":"2023","journal-title":"J Bone Miner Res"},{"key":"R36-20260831","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/08903344221146472","article-title":"Milk calcium and phosphorus in Ugandan women with HIV on tenofovir-based antiretroviral therapy.","volume":"39","author":"Nabwire","year":"2023","journal-title":"J Hum Lact"},{"key":"R37-20260831","doi-asserted-by":"crossref","first-page":"e0271525","DOI":"10.1371\/journal.pone.0271525","article-title":"Adverse maternofoetal outcomes associated with ionised calcaemia, total calcaemia, albuminaemia, and calcium supplementation in pregnancy: analysis from a resource-limited setting.","volume":"17","author":"Ajong","year":"2022","journal-title":"PLoS One"},{"key":"R38-20260831","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/QAD.0000000000003785","article-title":"Maternal breastfeeding and education impact infant growth and development more than in-utero HIV\/antiretroviral therapy exposure in context of universal antiretroviral therapy.","volume":"38","author":"Cherkos","year":"2024","journal-title":"AIDS"},{"key":"R39-20260831","doi-asserted-by":"crossref","first-page":"e0250828","DOI":"10.1371\/journal.pone.0250828","article-title":"Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health.","volume":"16","author":"Kinai","year":"2021","journal-title":"PLoS One"},{"key":"R40-20260831","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment.","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat"},{"key":"R41-20260831","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12072-015-9662-9","article-title":"Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.","volume":"10","author":"Wang","year":"2016","journal-title":"Hepatol Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:01:40Z","timestamp":1788195700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049131","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2025-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}